Novo sues Lilly over marketing of insulin cartridges:
This article was originally published in Clinica
Executive Summary
Danish company Novo Nordisk, the world's largest insulin producer, is suing its main rival, US company Eli Lilly. Novo alleges that Lilly is marketing its human insulin cartridges in packaging containing misleading statements which was giving users the impression that Novo had approved the use of Lilly cartridges in its pens.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.